Q-Line Biotech
Table of Contents
- 01 IPO Description
- 02 IPO Parameters
- 03 IPO Roadmap
- 04 GMP History
- 05Q-Line Biotech IPO Market Lot
- 06 Q-Line Biotech IPO Details
- 07 IPO Reservation
- 08 Q-Line Biotech IPO Anchor Investors
- 09 Q-Line Biotech IPO Dates
- 10 Promoters and Holding Pattern
- 11 Objects of the Issue & Utilisation of Proceeds
- 12 About Q-Line Biotech IPO
- 13 Q-Line Biotech IPO Company Financial Report
- 14 Q-Line Biotech IPO Valuation – FY2025
- 15 Peer Group Comparison
- 16 IPO Lead Managers aka Merchant Bankers
IPO PARAMETERS
IPO ROADMAP
Grey Market Premium HISTORY
| Date | GMP (₹) | Daily Change | Gain (%) |
|---|---|---|---|
| 20 May 2026 | ₹110.50 | - | 32.22% |
Q-Line Biotech IPO MARKET LOT
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 | 800 | ₹274,400 |
| Retail Maximum | 2 | 800 | ₹274,400 |
| S-HNI Minimum | 3 | 1,200 | ₹411,600 |
| S-HNI Maximum | 7 | 2,800 | ₹960,400 |
| B-HNI Minimum | 8 | 3,200 | ₹1,097,600 |
Q-Line Biotech IPO DETAILS
| Particulars | Details |
|---|---|
| IPO Open Date | May 21, 2026 |
| IPO Close Date | May 25, 2026 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹326 to ₹343 Per Share |
| Issue Size | Approx ₹214 Crores, 62,53,200 Equity Shares |
| Fresh Issue | Approx ₹214 Crores, 62,53,200 Equity Shares |
| Issue Type | Book build Issue |
| IPO Listing | NSE SME |
IPO RESERVATION
| Investor Category | Share Offered | Shares (%) |
|---|---|---|
| Anchor Investor | – Shares | -% |
| QIB (Ex. Anchor) | 29,69,200 Shares | 50% |
| NII Shares Offered | 8,91,600 Shares | 15% |
| Retail Shares Offered | 20,79,200 Shares | 35% |
Q-Line Biotech IPO Anchor INVESTORS
| Particulars | Details |
|---|---|
| Anchor Bidding Date | 2026 |
| Anchor Investors List | |
| Shares Offered | [.] Shares |
| Anchor Size | [.] Cr. |
| Lock-in Period End Date 50% Shares (30 Days) | 2026 |
| Lock-in Period End Date 50% Shares (90 Days) | 2026 |
Q-Line Biotech IPO DATES
The Q-Line Biotech IPO date is May 21, and the close date is May 25. The Q-Line Biotech IPO allotment will be finalized on May 26, and the IPO listing on May 29.
| Event | Date |
|---|---|
| IPO Open Date | May 21, 2026 |
| IPO Close Date | May 25, 2026 |
| Basis of Allotment | May 26, 2026 |
| Refunds | May 27, 2026 |
| Credit to Demat Account | May 27, 2026 |
| IPO Listing Date | May 29, 2026 |
| IPO Bidding Cut-off Time | May 25, 2026 – 5 PM |
Promoters and Holding PATTERN
The promoters of the company are Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal.
| Particular | Shares | % Share |
|---|---|---|
| Promoter Holding Pre Issue | 1,70,74,999 | 96.77% |
| Promoter Holding Post Issue | 2,33,28,199 | -% |
Objects of the Issue & Utilisation of PROCEEDS
| Purpose | Crores |
|---|---|
| To Meet Working Capital Requirements | ₹110.00 |
| Repayment of Certain Borrowing Availed by the Company, in Part or Full | ₹90.00 |
| General Corporate Purpose | ₹- |
About Q-Line Biotech IPO
Since its incorporation in 2013, Q-Line Biotech has been involved in the healthcare and diagnostic industry. The firm is known for manufacturing and supplying In-Vitro Diagnostic (IVD) products, medical diagnostic equipment, reagents, rapid test kits, and pathology instruments. The firm has been known to offer high-quality products and services at an affordable price range.
Q-Line Biotech has over 15 years of experience in the diagnostic industry and has served 150+ national and international clients. Moreover, the company also has 12 years of experience in developing and manufacturing various products. Its product range includes haematology, POC testing, clinical chemistry, molecular diagnostics, rapid tests, ELISA, and special diagnostics.
Q-Line Biotech IPO Company Financial REPORT
Amount ₹ in Crores
| Period Ended | Revenue | Expense | PAT | Assets |
|---|---|---|---|---|
| 2023 | ₹184.81 | ₹154.97 | ₹32.10 | ₹251.58 |
| 2024 | ₹206.45 | ₹175.85 | ₹34.44 | ₹339.25 |
| 2025 | ₹322.58 | ₹261.43 | ₹28.13 | ₹455.49 |
| Dec 2025 | ₹236.50 | ₹186.96 | ₹38.69 | ₹561.34 |
Q-Line Biotech IPO Valuation – FY2025
Check Q-Line Biotech IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
|---|---|
| ROE | 17.66% |
| ROCE | 23.74% |
| EBITDA Margin | 22.73% |
| PAT Margin | 8.97% |
| Debt to Equity Ratio | 0.87 |
| Earning Per Share (EPS) | ₹28.63 (Basic) |
| Price/Earning P/E Ratio | N/A |
| Return on Net Worth (RoNW) | 23.74% |
| Net Asset Value (NAV) | ₹120.60 |
Peer Group COMPARISON
There are no listed companies in India.
IPO Lead Managers aka Merchant BANKERS
- Hem Securities Ltd.
- Share India Capital Services Pvt. Ltd.